Streetbeat News

Analyst Ratings

TNDM

Citigroup analyst Joanne Wuensch has maintained a Neutral rating on Tandem Diabetes Care (NASDAQ:TNDM) and increased the price target from $25 to $31.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 3:16 pm

QNRX

Maxim Group analyst Naz Rahman has maintained a Buy rating on Quoin Pharmaceuticals (NASDAQ:QNRX) but has lowered the price target from $15 to $4.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 3:15 pm

GETY

Citigroup analyst Ronald Josey maintains a Buy rating on Getty Images Holdings (NYSE:GETY) and raises the price target from $5.5 to $6.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 3:13 pm

HEAR

Maxim Group analyst Jack Vander Aarde maintains a Buy rating on Turtle Beach (NASDAQ:HEAR) and raises the price target from $18 to $24.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 3:12 pm

MDGL

Citigroup analyst David Lebovitz has maintained a Buy rating on Madrigal Pharmaceuticals (MDGL) and increased the price target from $382 to $389.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 3:10 pm

ACN

Citigroup analyst Ashwin Shirvaikar maintains a Buy rating on Accenture (ACN) and raises the price target from $385 to $430.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 3:05 pm

ULTA

BMO Capital analyst Simeon Siegel maintains a Market Perform rating on Ulta Beauty (ULTA) and raises the price target from $485 to $540.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 3:04 pm

GES

Analyst ratings for Guess (NYSE:GES) show varied sentiments, with recent evaluations ranging from bullish to bearish. The average 12-month price target is now $25.75, down 8.04% from the previous $28.00. Analyst actions include maintaining, raising, and lowering ratings and price targets, reflecting their reaction to Guess's performance and market conditions. Guess's financials indicate strong profitability and financial health but a higher level of financial risk due to a debt-to-equity ratio above industry average.

Portfolio Pulse from Benzinga Insights

March 15, 2024 | 3:01 pm

TERN

BMO Capital analyst Etzer Darout has maintained an Outperform rating on Terns Pharma (NASDAQ:TERN) and increased the price target from $18 to $19.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 3:01 pm

DOCS

Doximity (NYSE:DOCS) received mixed analyst ratings in the last quarter, with a shift towards a more cautious stance. The recent ratings show a trend from indifferent to somewhat bearish, with 5 indifferent and 1 somewhat bearish rating. Analysts have updated their 12-month price targets, indicating an average target of $29.00, a high of $32.00, and a low of $25.00, reflecting a 16% increase from the previous average of $25.00. Doximity's financial performance is strong, with significant revenue growth, high net margin, and solid returns on equity and assets, alongside a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 15, 2024 | 3:01 pm